2017
DOI: 10.1093/schbul/sbx021.118
|View full text |Cite
|
Sign up to set email alerts
|

79. D2/D3 Dopamine Receptor Binding With [F-18] Fallypride Correlates of Executive Function in Medication-Naive Patients With Schizophrenia

Abstract: individuals at clinical high risk (CHR) for developing schizophrenia is not well characterized. Methods: We studied youth (ages 11-30) meeting CHR for psychosis criteria (n = 30), individuals early in their schizophrenia illness (ESZ; n = 22), and healthy adolescents and young adults (HC; n = 72). Functional magnetic resonance imaging was collected during Go/NoGo response inhibition task performance. Voxelwise main effects of Group (p<.001 height threshold, family-wise error corrected P < .05) for incorrect No… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…In recent years, antagonist drugs have shown better properties than agonist compounds for binding with dopamine D2 receptor. The main antagonist drugs are atypical antipsychotics [26], cinnarizine [27], chloroethylnorapomorphine [28], desmethoxyfallypride [29], domperidone [30], metoclopramide [31], eticlopride [32], fallypride [33], hydroxyzine [34] and itopride [35].…”
Section: Introductionmentioning
confidence: 99%
“…In recent years, antagonist drugs have shown better properties than agonist compounds for binding with dopamine D2 receptor. The main antagonist drugs are atypical antipsychotics [26], cinnarizine [27], chloroethylnorapomorphine [28], desmethoxyfallypride [29], domperidone [30], metoclopramide [31], eticlopride [32], fallypride [33], hydroxyzine [34] and itopride [35].…”
Section: Introductionmentioning
confidence: 99%